Oncology Franchise Support

Impact acceleration of trial awareness, and reduced competitive lag time

Mission: Rally a Team Behind a Promising Agent That will Be Second-To-Market in Its Class

Key Issues:                                               

• New class of drugs remain relatively unknown within oncology community
• Agent facing a significant lag with its nearest competitor
• Targeted registration indication facing recently increased competition

Results and Implications:

• Trial accrual beats accrual targets after 5 months
• Class and drug awareness increase of 72% according to a third-party auditor
• Team Roadmap nominated as Best Practice
• Team leaders awarded for accomplishments
• Competitive lag cut down by 68%